Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 10 aug 2015 - 22:00

Statutaire naam Galapagos NV

Titel DARWIN 2 24-week monotherapy data in RA confirm previous results and support best-in-class potential for filgotinib

Bericht ACR50 responses up to 45% as once-daily monotherapy DAS28(CRP) low disease activity up to 50% Similar efficacy at 100 and 200 mg Safety profile in DARWIN 2 consistent with previous filgotinib RA studies These data complete the delivery of the final data package to AbbVie; triggers the licensing decision period Webcast presentation of the results to be held on 11 August 2015, 16.00 CET/10 AM EDT/ 8 AM PDT, +32 2 404 0660, access code 1973880, more call number info further down

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201508100000000015_DARWIN 2 24-week monotherapy data in RA confirm previous results and support best-in-class potential for filgotinib.pdf (opens in a new window)

Datum laatste update: 25 maart 2025